Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) IV: Prognosis for End-Stage Renal Disease and Biomarker Validation
多囊肾病放射影像研究联盟 (CRISP) IV:终末期肾病的预后和生物标志物验证
基本信息
- 批准号:9906761
- 负责人:
- 金额:$ 67.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-04-01 至 2022-03-30
- 项目状态:已结题
- 来源:
- 关键词:AlabamaAncillary StudyAutosomal Dominant Polycystic KidneyBiochemicalBiochemical GeneticsBiochemical MarkersBiological MarkersBiological Specimen BanksBloodCessation of lifeChicagoClinicClinical TrialsCohort StudiesCommunitiesCreatinineDataData SetDevelopmentDiseaseDisease ProgressionDisease modelEnd stage renal failureEnrollmentEvaluationGenesGenetic MarkersGoalsGrowthHealthImageImage AnalysisIndividualIntervention TrialKansasKidneyLifeLife ExpectancyLogistic RegressionsLongitudinal observational studyMeasurementMedical centerModelingOutcomeParticipantPatient CarePatientsPhenotypePolycystic Kidney DiseasesPredictive ValuePrognostic MarkerProspective cohort studyQuality of lifeRenal Blood FlowRenal functionResearch PersonnelResourcesRoleSamplingSerumShapesSiteTechniquesTestingTherapy trialTimeUnited StatesUniversitiesUrineValidationVisitartificial neural networkbasebiomarker discoverybiomarker validationblood flow measurementclassification treesclinical carecohortdesigndisease natural historyexosomefollow-upgenetic variantimaging geneticsimaging studyimprovedindividual patientinnovationmodel buildingnovelnovel markernovel strategiesnovel therapeuticsoutcome forecastpredictive modelingpredictive toolspreservationprognosticprognostic toolprognostic valueprospectiveproteomic signatureradiological imagingurinaryyoung adult
项目摘要
Project Summary
The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) is a unique, longitudinal,
observational cohort study of 241 autosomal dominant polycystic kidney disease (ADPKD) patients that began
in 2000. The consortium consists of researchers at University of Alabama, University of Chicago, Emory
University, University of Kansas Medical Center, Mayo Clinic, and University of Pittsburgh. The broad, long-
term objectives of CRISP are to define the natural history of the disease and to discover prognostic biomarkers
in early disease that can accurately predict long-term renal outcomes. The goals of CRISP IV are to continue
follow-up of the CRISP cohort for 5 more years so as to refine models of CKD progression and strengthen the
association between htTKV and renal outcomes, to validate disease models using existing and additional
follow-up data from the HALT PKD study, and to incorporate powerful emerging imaging, genetic and
biochemical biomarkers to improve the accuracy of prognostication for individual patients. To achieve this, the
specific aims are: Aim 1. Continue follow-up of CRISP and HALT participants. All CRISP participants that have
not reached ESRD, together with HALT Study A participants followed at CRISP sites, will be followed up with
annual serum creatinine measurements. Aim 2. Develop improved models to predict GFR trajectories and
progression to ESRD. Existing logistic regression and trajectory models will be refined and new approaches
such as artificial neural network and classification tree models developed, using CRISP data for model fitting
and HALT-A data for external validation. Aim 3. Develop novel imaging, biochemical and genetic biomarkers of
disease progression. Highly promising new biomarkers that are emerging from ancillary studies or being
developed in parallel ongoing studies at the CRISP centers, will be evaluated for their ability to improve the
accuracy of prognostic models.
项目摘要
多囊肾病放射影像研究联合会(CRISP)是一家独特的、纵向的、
241例常染色体显性遗传性多囊肾病患者的观察队列研究
在2000年。该联盟由阿拉巴马大学、芝加哥大学、埃默里大学的研究人员组成
大学、堪萨斯大学医学中心、梅奥诊所和匹兹堡大学。宽阔的,长的-
CRISP的术语目标是定义疾病的自然病史并发现预后生物标志物
在早期疾病中,可以准确地预测长期肾脏结果。CRISP IV的目标是继续
对CRISPING队列进行5年以上的随访,以完善CKD进展模型并加强
HTTKV和肾脏结果之间的关联,以验证使用现有和额外的疾病模型
来自HALT PKD研究的后续数据,并结合强大的新兴成像、遗传学和
生化生物标记物,以提高个体患者预测的准确性。为了实现这一点,
具体目标是:目标1。继续跟踪清晰度和停止参与者。所有干练的参与者都有
未达到ESRD,以及HALT研究A参与者在CRISP地点进行跟踪,将得到后续
每年一次的血肌酐测量。目标2.开发改进的模型来预测GFR轨迹和
进展为终末期肾病。现有的Logistic回归和轨迹模型将得到改进和新的方法
如人工神经网络和分类树模型等,利用CRISP数据进行模型拟合
和HALT-A数据用于外部验证。目的3.开发新的成像、生化和遗传生物标记物
疾病的发展。从辅助研究中涌现出来的极有希望的新生物标记物
在CRISP中心同时进行的研究,将评估它们改善
预测模型的准确性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alan S Yu其他文献
Alan S Yu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alan S Yu', 18)}}的其他基金
Biomedical Research Core 3 - Clinical Research Core
生物医学研究核心 3 - 临床研究核心
- 批准号:
10475048 - 财政年份:2020
- 资助金额:
$ 67.54万 - 项目类别:
Biomedical Research Core 3 - Clinical Research Core
生物医学研究核心 3 - 临床研究核心
- 批准号:
10059768 - 财政年份:2020
- 资助金额:
$ 67.54万 - 项目类别:
Biomedical Research Core 3 - Clinical Research Core
生物医学研究核心 3 - 临床研究核心
- 批准号:
10214616 - 财政年份:2020
- 资助金额:
$ 67.54万 - 项目类别:
Biomedical Research Core 3 - Clinical Research Core
生物医学研究核心 3 - 临床研究核心
- 批准号:
10686076 - 财政年份:2020
- 资助金额:
$ 67.54万 - 项目类别:
Role of claudin-2 in Calcium Homeostasis and Kidney Stone Disease
Claudin-2 在钙稳态和肾结石疾病中的作用
- 批准号:
10238078 - 财政年份:2019
- 资助金额:
$ 67.54万 - 项目类别:
Role of claudin-2 in Calcium Homeostasis and Kidney Stone Disease
Claudin-2 在钙稳态和肾结石疾病中的作用
- 批准号:
10020951 - 财政年份:2019
- 资助金额:
$ 67.54万 - 项目类别:
CRISP III - Kansas Polycystic Kidney Imaging Program Supplemental Request
CRISP III - 堪萨斯州多囊肾成像计划补充请求
- 批准号:
9269449 - 财政年份:2016
- 资助金额:
$ 67.54万 - 项目类别:
Randomized, controlled pilot study of nicotinamide in polycystic kidney disease
烟酰胺治疗多囊肾病的随机对照试验研究
- 批准号:
8807460 - 财政年份:2015
- 资助金额:
$ 67.54万 - 项目类别:
Randomized, controlled pilot study of nicotinamide in polycystic kidney disease
烟酰胺治疗多囊肾病的随机对照初步研究
- 批准号:
9136856 - 财政年份:2015
- 资助金额:
$ 67.54万 - 项目类别:
Structure-Function Studies of Tight Junction Membrane Proteins
紧密连接膜蛋白的结构-功能研究
- 批准号:
8152114 - 财政年份:2010
- 资助金额:
$ 67.54万 - 项目类别:
相似海外基金
Coronary Artery Calcium in the PRagmatic EValuation of evENTs And Benefits of Lipid lowering in the Elderly: CAC PREVENTABLE Ancillary Study
冠状动脉钙对老年人降脂事件和益处的实用评估:CAC 可预防的辅助研究
- 批准号:
10674482 - 财政年份:2021
- 资助金额:
$ 67.54万 - 项目类别:
A Longitudinal Study of Periodontal Infections and Alzheimer's Disease: The WHICAP Ancillary Study of Oral Health
牙周感染和阿尔茨海默病的纵向研究:口腔健康的 WHICAP 辅助研究
- 批准号:
10381292 - 财政年份:2021
- 资助金额:
$ 67.54万 - 项目类别:
The PREVENTABLE Physical Performance Ancillary Study
可预防的身体表现辅助研究
- 批准号:
10366941 - 财政年份:2021
- 资助金额:
$ 67.54万 - 项目类别:
The PREVENTABLE Physical Performance Ancillary Study
可预防的身体表现辅助研究
- 批准号:
10495229 - 财政年份:2021
- 资助金额:
$ 67.54万 - 项目类别:
StAtins Use in intRacereberal hemorrhage patieNts MRI (SATURN MRI) Ancillary Study
他汀类药物在脑出血患者中的使用 MRI (SATURN MRI) 辅助研究
- 批准号:
10179775 - 财政年份:2021
- 资助金额:
$ 67.54万 - 项目类别:
Mechanistic Ancillary Study to the Natural History Study of ADO2 to Determine Clinical Severity
ADO2 自然史研究的机制辅助研究以确定临床严重程度
- 批准号:
10375070 - 财政年份:2021
- 资助金额:
$ 67.54万 - 项目类别:
A Longitudinal Study of Periodontal Infections and Alzheimer's Disease: The WHICAP Ancillary Study of Oral Health
牙周感染和阿尔茨海默病的纵向研究:口腔健康的 WHICAP 辅助研究
- 批准号:
10631203 - 财政年份:2021
- 资助金额:
$ 67.54万 - 项目类别:
Coronary Artery Calcium in the PRagmatic EValuation of evENTs And Benefits of Lipid lowering in the Elderly: CAC PREVENTABLE Ancillary Study
冠状动脉钙对老年人降脂事件和益处的实用评估:CAC 可预防的辅助研究
- 批准号:
10296788 - 财政年份:2021
- 资助金额:
$ 67.54万 - 项目类别:
COCOA PAD II Trial: Microbiome Ancillary Study
COCOA PAD II 试验:微生物组辅助研究
- 批准号:
10610072 - 财政年份:2021
- 资助金额:
$ 67.54万 - 项目类别:
An MRI Ancillary Study of Malaria Fever Control RCT
疟疾发热控制的 MRI 辅助随机对照试验
- 批准号:
10343754 - 财政年份:2020
- 资助金额:
$ 67.54万 - 项目类别: